Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap, S.Demirci, U.Bugdayci, F.Tural, D.Korkmaz, T.Paydas, S.Yilmaz, C.2024-06-122024-06-1220191556-08641556-1380https://doi.org/10.1016/j.jtho.2019.08.1166https://hdl.handle.net/20.500.14551/18273[Abstract Not Available]en10.1016/j.jtho.2019.08.1166info:eu-repo/semantics/openAccessALK PositiveROS1 PositiveLorlatinibAdvanced Stage Lung CancerLorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyConference Object1410S558S559Q1WOS:000492162203082